Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Calcium Supplementation Attenuates Disruptions in Calcium Homeostasis during Exercise.

Sherk VD, Wherry SJ, Barry DW, Shea KL, Wolfe P, Kohrt WM.

Med Sci Sports Exerc. 2017 Jul;49(7):1437-1442. doi: 10.1249/MSS.0000000000001239.

2.

Timing of Ibuprofen Use and Musculoskeletal Adaptations to Exercise Training in Older Adults.

Jankowski CM, Shea K, Barry DW, Linnebur SA, Wolfe P, Kittelson J, Schwartz RS, Kohrt WM.

Bone Rep. 2015 Jan 1;1:1-8.

3.

Calcium supplementation and parathyroid hormone response to vigorous walking in postmenopausal women.

Shea KL, Barry DW, Sherk VD, Hansen KC, Wolfe P, Kohrt WM.

Med Sci Sports Exerc. 2014 Oct;46(10):2007-13. doi: 10.1249/MSS.0000000000000320.

4.

Bone loss over 1 year of training and competition in female cyclists.

Sherk VD, Barry DW, Villalon KL, Hansen KC, Wolfe P, Kohrt WM.

Clin J Sport Med. 2014 Jul;24(4):331-6. doi: 10.1097/JSM.0000000000000050.

5.

Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels.

Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, Wolfe P, Kohrt WM, Ruscin JM, Kittelson J, Cress ME, Ballard R, Schwartz RS.

J Clin Endocrinol Metab. 2013 May;98(5):1891-900. doi: 10.1210/jc.2012-3695. Epub 2013 Mar 26.

6.

Increasing dietary fat elicits similar changes in fat oxidation and markers of muscle oxidative capacity in lean and obese humans.

Bergouignan A, Gozansky WS, Barry DW, Leitner W, MacLean PS, Hill JO, Draznin B, Melanson EL.

PLoS One. 2012;7(1):e30164. doi: 10.1371/journal.pone.0030164. Epub 2012 Jan 12.

7.

Acute calcium ingestion attenuates exercise-induced disruption of calcium homeostasis.

Barry DW, Hansen KC, van Pelt RE, Witten M, Wolfe P, Kohrt WM.

Med Sci Sports Exerc. 2011 Apr;43(4):617-23. doi: 10.1249/MSS.0b013e3181f79fa8.

8.

Laryngopharyngeal reflux: More questions than answers.

Barry DW, Vaezi MF.

Cleve Clin J Med. 2010 May;77(5):327-34. doi: 10.3949/ccjm.77a.09121. Review.

PMID:
20439565
9.

Timing of ibuprofen use and bone mineral density adaptations to exercise training.

Kohrt WM, Barry DW, Van Pelt RE, Jankowski CM, Wolfe P, Schwartz RS.

J Bone Miner Res. 2010 Jun;25(6):1415-22. doi: 10.1002/jbmr.24.

10.

When energy balance is maintained, exercise does not induce negative fat balance in lean sedentary, obese sedentary, or lean endurance-trained individuals.

Melanson EL, Gozansky WS, Barry DW, Maclean PS, Grunwald GK, Hill JO.

J Appl Physiol (1985). 2009 Dec;107(6):1847-56. doi: 10.1152/japplphysiol.00958.2009. Epub 2009 Oct 15.

11.

Muscle forces or gravity: what predominates mechanical loading on bone?

Kohrt WM, Barry DW, Schwartz RS.

Med Sci Sports Exerc. 2009 Nov;41(11):2050-5. doi: 10.1249/MSS.0b013e3181a8c717.

12.

Exercise and the preservation of bone health.

Barry DW, Kohrt WM.

J Cardiopulm Rehabil Prev. 2008 May-Jun;28(3):153-62. doi: 10.1097/01.HCR.0000320065.50976.7c.

PMID:
18496313
13.

BMD decreases over the course of a year in competitive male cyclists.

Barry DW, Kohrt WM.

J Bone Miner Res. 2008 Apr;23(4):484-91.

14.

Acute effects of 2 hours of moderate-intensity cycling on serum parathyroid hormone and calcium.

Barry DW, Kohrt WM.

Calcif Tissue Int. 2007 Jun;80(6):359-65. Epub 2007 Jun 5.

PMID:
17549534
15.

Patient and physician perceptions of timely access to care.

Barry DW, Melhado TV, Chacko KM, Lee RS, Steiner JF, Kutner JS.

J Gen Intern Med. 2006 Feb;21(2):130-3. Epub 2005 Dec 7.

16.

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team.

JAMA. 2004 Jul 14;292(2):180-9.

PMID:
15249567
17.

Clinical and laboratory diagnosis of acute renal failure.

Anderson RJ, Barry DW.

Best Pract Res Clin Anaesthesiol. 2004 Mar;18(1):1-20. Review.

PMID:
14760871
18.

Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.

Rousseau FS, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, Hulett L, Wang LH, Quinn JB, Barry DW; FTC-102 Clinical Trial Group.

J Infect Dis. 2003 Dec 1;188(11):1652-8. Epub 2003 Oct 31.

PMID:
14639535
19.

Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.

Szczech GM, Furman P, Painter GR, Barry DW, Borroto-Esoda K, Grizzle TB, Blum MR, Sommadossi J, Endoh R, Niwa T, Yamamoto M, Moxham C.

Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.

20.

New initiatives in combination antiretroviral chemotherapy.

Rooney JF, Warwick JC, Elkins MM, St Clair MH, Barry DW.

Adv Exp Med Biol. 1996;394:373-82. Review. No abstract available.

PMID:
8815702
21.

Rapid screening of antiretroviral combinations.

St Clair M, Pennington KN, Rooney J, Barry DW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S24-7. Review.

PMID:
8595504
22.

Inter-Company Collaboration Combination Trials. Clinical Trial Subcommittee of the Inter-Company Collaboration for AIDS Drug Development.

Soo W, Nauss-Karol C, Elkins M, Rooney J, Barry DW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S92-6.

PMID:
7552520
23.

In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.

St Clair MH, Pennington KN, Rooney J, Barry DW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S83-91.

PMID:
7552518
24.

Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.

Ellis MN, Waters R, Hill EL, Lobe DC, Selleseth DW, Barry DW.

Antimicrob Agents Chemother. 1989 Mar;33(3):304-10.

25.

Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program.

Creagh-Kirk T, Doi P, Andrews E, Nusinoff-Lehrman S, Tilson H, Hoth D, Barry DW.

JAMA. 1988 Nov 25;260(20):3009-15.

PMID:
3263514
26.

Spectrum of antiviral activity and mechanism of action of zidovudine. An overview.

Furman PA, Barry DW.

Am J Med. 1988 Aug 29;85(2A):176-81. Review.

PMID:
3044082
27.

Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus.

LaFon SW, Lehrman SN, Barry DW.

J Infect Dis. 1988 Aug;158(2):503. No abstract available.

PMID:
3042884
28.

HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail.

Parks WP, Parks ES, Fischl MA, Leuther MD, Allain JP, Nusinoff-Lehrman S, Barry DW, Makuch RW.

J Acquir Immune Defic Syndr. 1988;1(2):125-30.

PMID:
3145972
29.

Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Ellis MN, Keller PM, Fyfe JA, Martin JL, Rooney JF, Straus SE, Lehrman SN, Barry DW.

Antimicrob Agents Chemother. 1987 Jul;31(7):1117-25.

30.

Induction of acyclovir-resistant mutants of herpes simplex virus type I in athymic nude mice.

Ellis MN, Martin JL, Lobe DC, Johnsrude JD, Barry DW.

J Antimicrob Chemother. 1986 Oct;18 Suppl B:95-101.

PMID:
3025159
31.

Extended acyclovir therapy for herpes genitalis: changes in virus sensitivity and strain variation.

Lehrman SN, Hill EL, Rooney JF, Ellis MN, Barry DW, Straus SE.

J Antimicrob Chemother. 1986 Oct;18 Suppl B:85-94.

PMID:
3025158
32.

Clinical and laboratory experience with acyclovir-resistant herpes viruses.

Barry DW, Lehrman SN, Ellis MN.

J Antimicrob Chemother. 1986 Oct;18 Suppl B:75-84.

PMID:
3025157
33.
34.

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW, et al.

Lancet. 1986 Mar 15;1(8481):575-80.

PMID:
2869302
35.

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S.

Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100.

36.

Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates.

Martin JL, Ellis MN, Keller PM, Biron KK, Lehrman SN, Barry DW, Furman PA.

Antimicrob Agents Chemother. 1985 Aug;28(2):181-7.

37.

Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.

Ellis MN, Barry DW.

Antimicrob Agents Chemother. 1985 Feb;27(2):167-71.

38.

Viral resistance, clinical experience.

Barry DW, Nusinoff-Lehrman S, Ellis MN, Biron KK, Furman PA.

Scand J Infect Dis Suppl. 1985;47:155-64.

PMID:
3006230
39.

In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients.

McLaren C, Corey L, Dekket C, Barry DW.

J Infect Dis. 1983 Nov;148(5):868-75.

PMID:
6313820
40.

Virus resistance in clinical practice.

Dekker C, Ellis MN, McLaren C, Hunter G, Rogers J, Barry DW.

J Antimicrob Chemother. 1983 Sep;12 Suppl B:137-52. Review.

PMID:
6313593
41.

Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child.

Sibrack CD, Gutman LT, Wilfert CM, McLaren C, St Clair MH, Keller PM, Barry DW.

J Infect Dis. 1982 Nov;146(5):673-82.

PMID:
6290575
42.

Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates.

McLaren C, Sibrack CD, Barry DW.

Am J Med. 1982 Jul 20;73(1A):376-9.

PMID:
6285726
43.

Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.

Sibrack CD, McLaren C, Barry DW.

Am J Med. 1982 Jul 20;73(1A):372-5.

PMID:
6285725
44.

Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy.

Burns WH, Saral R, Santos GW, Laskin OL, Lietman PS, McLaren C, Barry DW.

Lancet. 1982 Feb 20;1(8269):421-3.

PMID:
6121091
45.

Poor rectal absorption of trimethoprim/sulphamethoxazole in treating Pneumocystis carinii pneumonia.

Dorr RT, Powell JR, Heick M, Barry DW.

Postgrad Med J. 1981 Feb;57(664):123-5.

46.

Gastrointestinal tuberculosis mimicking cancer--a reminder.

Murillo J, Wells GM, Barry DW, Calia FM.

Am J Gastroenterol. 1978 Jul;70(1):76-8.

PMID:
696717
47.
48.

Evaluation and control of vaccines for the National Influenza Immunization Program.

Barry DW, Mayner RE, Meisler JM, Seligmann EB Jr.

J Infect Dis. 1977 Dec;136 Suppl:S407-14.

PMID:
606764
49.

Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines.

Ennis FA, Mayner RE, Barry DW, Manischewitz JE, Dunlap RC, Verbonitz MW, Bozeman RM, Schild GC.

J Infect Dis. 1977 Dec;136 Suppl:S397-406.

PMID:
606763
50.

Induction of tubuloreticular inclusions in human lymphoma cells (Raji line) related to S-phase treatment with halogenated pyrimidines.

Hulanicka B, Barry DW, Grimley PM.

Cancer Res. 1977 Jul;37(7 Pt 1):2105-13. No abstract available.

Supplemental Content

Loading ...
Support Center